Tumor Immunology Round Table

N-acetyllactosamine (lacNAC) reverts human TIL anergy ex vivo.

April 20, 2008

Hello In this edition of the podcast I will discuss a paper published by Demotte and collaborators published this year in the journal Immunity "Restoring the association of the T cell receptor with CD8 reverses anergy in human tumor-infiltrating lymphocytes" vol 28, pag 414 of April 2008. In this paper the authors show that LacNAC can compete for galectin-3 binding freeing TCR from TIL to colocalize with CD8 and allow the recovery of efector functional on ex vivo freshly isolated TIL from ovarian cancer and gastric cancer. See you next time.

Podparadise.com neither hosts nor alters podcast files. All content © its respective owners.